악성 늑막 삼출증에서의 비디오 흉강경하 탈크 분무의 효과 및 장점 분석

Video-assisted Talc Poudrage for the Treatment of Malignant Pleural Effusion: Analysis of Effects and Benefits

  • 송인학 (순천향대학교 의과대학 천안병원 흉부외과학교실) ;
  • 장원호 (순천향대학교 의과대학 서울병원 흉부외과학교실) ;
  • 최창우 (순천향대학교 의과대학 구미병원 흉부외과학교실) ;
  • 손진성 (순천향대학교 의과대학 천안병원 흉부외과학교실) ;
  • 김동현 (순천향대학교 의과대학 천안병원 흉부외과학교실) ;
  • 백강석 (순천향대학교 의과대학 천안병원 흉부외과학교실) ;
  • 염욱 (순천향대학교 의과대학 서울병원 흉부외과학교실) ;
  • 김현조 (순천향대학교 의과대학 서울병원 흉부외과학교실)
  • Song, In-Hag (Department of Thoracic and Cardiovascular Surgery, Cheonan Hospital, College of Medicine, Soonchunhyang University) ;
  • Chang, Won-Ho (Department of Thoracic and Cardiovascular Surgery, Seoul Hospital, College of Medicine, Soonchunhyang University) ;
  • Choi, Chang-Woo (Department of Thoracic and Cardiovascular Surgery, Gumi Hospital, College of Medicine, Soonchunhyang University) ;
  • Son, Jin-Sung (Department of Thoracic and Cardiovascular Surgery, Cheonan Hospital, College of Medicine, Soonchunhyang University) ;
  • Kim, Dong-Hyun (Department of Thoracic and Cardiovascular Surgery, Cheonan Hospital, College of Medicine, Soonchunhyang University) ;
  • Baek, Kang-Seok (Department of Thoracic and Cardiovascular Surgery, Cheonan Hospital, College of Medicine, Soonchunhyang University) ;
  • Youm, Wook (Department of Thoracic and Cardiovascular Surgery, Seoul Hospital, College of Medicine, Soonchunhyang University) ;
  • Kim, Hyun-Jo (Department of Thoracic and Cardiovascular Surgery, Seoul Hospital, College of Medicine, Soonchunhyang University)
  • 발행 : 2007.07.05

초록

배경: 악성 늑막 삼출증은 암환자에서 흔히 나타나며 보존적 치료가 일반적인 치료 방법이다. Talc는 화학적 늑막유착술에 이용되는 가장 효과적인 경화제이지만, 투여경로에 대해서는 의견이 분분하다. 본 논문은 비디오 흉강경을 이용한 talc 분무(A군)를 흉관을 통한 전통적인 talc 현탁액 투여(B군)와 비교함으로써 비디오 흉강경을 통한 talc 분무의 장점과 효과를 분석하였다. 대상 및 방법: 2004년 12월부터 2006년 5월까지 악성 늑막 삼출증으로 화학적 늑막 유착술을 시행받은 20명을 대상으로 후향적으로 조사하였으며, 이 중 10명이 전신 마취하에 비디오 흉강경을 통한 talc 분무(A군)를 그리고 10명은 전통적인 talc 현탁액(B군)을 이용한 늑막유착술을 시행 받았다. 결과: 흉관의 평균 거치기간은 $7.0{\pm}4.0$일(A군)과 $6.7{\pm}3.6$(B군)이었고, 평균 재원 기간은 $24.3{\pm}9.4$일(A군)과 $30.7{\pm}21.5$일(B군)로 유의한 차이는 없었다. 증상도 두 군에서 모두 완화되었고 합병증도 없었다. 그러나 폐의 재팽창은 흉강경을 이용한 군에서 유의하게(p-value=0.011) 우수하였고, 외래 추적 관찰에서 호흡곤란도 흉강경을 이용한 군에서 더 많이 완화되었다(p-value=0.014). 결론: 비디오 흉강경을 통한 talc 분무는 병변을 직접 관찰하면서 흉수를 제거할 수 있고 필요한 경우 동시에 늑막 박피술을 시행할 수 있어 폐의 재팽창이 더 우수하며 이로 인해 호흡곤란도 더 많이 완화되며 늑막의 조직검사를 통한 진단을 할 수 있다는 장점이 있어 악성 흉수가 있는 환자에서 추천할 수 있는 방법이다.

Background: Malignant pleural effusion is a common condition in neoplastic patients and palliative therapy is the usual treatment. Talc has been generally accepted to be the most effective sclerosant for chemical pleurodesis, but the optimal route of administration remains controversy. We compared the results of video-assisted thoracoscopic talc poudrage (VTP) with administering a bedside talc slurry through a chest tube (BTS) for the treatment of malignant pleural effusion. Material and Method: From December 2004 to May 2006, 20 patients with malignant pleural effusion underwent chemical pleurodesis via VTP (group A, n=10), and BTS (group B, n=10). Result: The durations of chest tube placement after the procedure were $7.0{\pm}4.0$ days (group A) and $6.7{\pm}3.6$ days (group B). The hospital stays were $24.3{\pm}9.4$ days (group A) and $30.7{\pm}21.5$ days (group B), respectively. The symptoms of dyspnea were much more improved in group A (p-value=0.014) after discharge (mean f/u group $A=8.5{\pm}2.2$ months, group B $8.0{\pm}7.4$ months). The collapsed portions of lung were better expanded in group A than in group B (p-value=0.011). Conclusion: We recommend VTP for the selected patients with malignant pleural effusion because of the advantages of dissecting the fibrous peel to relieve the atelectasis and dyspnea, and excising the pleura for diagnosis with direct viewing of the lesion.

키워드

참고문헌

  1. Saffran L, Ost DE, Fein AM, Schiff MJ. Outpatient pleurodesis of malignant pleural effusions using a small-bore Pigtail catheter. Chest 2000;118:417-21 https://doi.org/10.1378/chest.118.2.417
  2. Cardillo G, Facciolo F, Carbone L, et al. Long-term follow- up of video-assisted talc pleurodesis in malignant recurrent pleural effusions. Eur J Cardiothorac Surg 2002;21: 302-6 https://doi.org/10.1016/S1010-7940(01)01130-7
  3. American Thoracic Society. Management of malignant pleural effusions. Am J Respir Crit Care Med 2000;162:1987-2001 https://doi.org/10.1164/ajrccm.162.5.ats8-00
  4. Meyer PC. Metastatic carcinoma of the pleura. Thorax 1966; 21:437-43 https://doi.org/10.1136/thx.21.5.437
  5. Marrazzo A, Noto A, Casa L, et al. Video-thoracoscopic surgical pleurodesis in the management of malignant pleural effusion: the importance of an early intervention. J Pain Symptom Manage 2005;30:75-9 https://doi.org/10.1016/j.jpainsymman.2005.01.015
  6. Hausheer PH, Yarbro JW. Diagnosis and treatment of malignant pleural effusion. Semin Oncol 1985;12:54-75
  7. Milanez RC, Vergas FS, Filomero LB, et al. Intrapleural talc for the treatment of malignant pleural effusions secondary to breast cancer. Cancer 1995;75:2688-92 https://doi.org/10.1002/1097-0142(19950601)75:11<2688::AID-CNCR2820751108>3.0.CO;2-3
  8. Kennedy L, Sahn SA. Talc pleurodesis for the treatment of pneunothorax and pleural effusion. Chest 1994;106:1215-22 https://doi.org/10.1378/chest.106.4.1215
  9. Yim APC, Chan ATC, Lee TW, et al. Thoracoscopic talc insufflation versus talc slurry for symptomatic malignant pleural effusion. Ann Thorac Surg 1996;62:1655-8 https://doi.org/10.1016/S0003-4975(96)00808-9
  10. Marel M, Zrustova M, Stasny B, et al. The incidence of pleural effusion in a well-defined region. Epidemiologic study in central Bohemia. Chest 1993;104:1486-9 https://doi.org/10.1378/chest.104.1.104
  11. Rodriguez-Panadero F, Rorders Naranjo F, Lopez-Mejias J. Pleural metastatic tumours and effusions: frequency and pathogenic mechanism in a post-mortem series. Eur Respir J 1989;2:366-9
  12. Porcel JM, Vives M. Etiology and pleural fluid characteristics of large and massive effusions. Chest 2003;124:978-83 https://doi.org/10.1378/chest.124.3.978
  13. Martini N, Bains MS, Beattie EJ. Indications for pleurectomy in malignant effusion. Cancer 1975;35:734-8 https://doi.org/10.1002/1097-0142(197503)35:3<734::AID-CNCR2820350328>3.0.CO;2-N
  14. Bersticker M, Oba J, LoCicero J III, Greene R. Optimal pleurodesis: a comparision study. Ann Thorac Surg 1993;55: 364-7 https://doi.org/10.1016/0003-4975(93)90998-W
  15. Bethune N. Pleural poudrage. J Thorac Cardiovasc Surg 1935;4:251-61
  16. Petrou M, Kaplan D, Goldstraw P. Management of recurrent malignant effusions. Cancer 1995;75:801-5 https://doi.org/10.1002/1097-0142(19950201)75:3<801::AID-CNCR2820750309>3.0.CO;2-H
  17. Wong PS, Goldstraw P. Pleuroperitoneal shunts: review. Br J Hosp Med 1993;50:16-21
  18. Lange P, Mortensen J, Groth S. Lung function 22-35 years after treatment idiopathic spontaneous pneumothorax with talc poudrage or simple drainage. Thorax 1988;43:559-61 https://doi.org/10.1136/thx.43.7.559
  19. Rehse DH, Aye RW, Florence MG. Respiratory failure following talc pleurodesis. Am J Surg 1999;177:437-40 https://doi.org/10.1016/S0002-9610(99)00075-6